Bristol Myers Squibb (CELG-RI) Other financing activities (2009 - 2022)

Bristol Myers Squibb has disclosed Other financing activities across 14 years of filings, most recently posting $179.0 million for Q4 2022.

• In Q4 2022, Other financing activities rose 6066.67% year-over-year to $179.0 million; the TTM figure through Dec 2022 stood at $984.0 million (up 53.51% YoY), while the FY2023 annual figure was $27.0 million, down 97.26% from the prior year.
• Other financing activities improved to $179.0 million in Q4 2022, from $53.0 million in the prior quarter.
• Over the last five years, Other financing activities for CELG-RI reached as high as $419.0 million in Q2 2022 and fell as low as -$58.0 million in Q1 2018.
• The 5-year median for Other financing activities is $35.5 million (2020), against an average of $103.0 million.
• Annual changes were most pronounced in 2019 — Other financing activities slumped 1400.0% — and 2020, when it jumped 17200.0%.
• A 5-year view of Other financing activities shows it stood at $1.0 million in 2018, then tumbled by 1400.0% to -$13.0 million in 2019, then surged by 2230.77% to $277.0 million in 2020, then plunged by 101.08% to -$3.0 million in 2021, then soared by 6066.67% to $179.0 million in 2022.
• According to Business Quant data, Other financing activities over the past three periods registered $179.0 million, $53.0 million, and $419.0 million for Q4 2022, Q3 2022, and Q2 2022 respectively.